Compugen to Present Research at the Single Cell Genomics 2025 Conference

HOLON, ISRAEL, Sept. 8, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery, powered by AI/ML today announced it will present research at the Single Cell Genomics 2025 Conference taking place September 15-17, 2025, in Stockholm, Sweden.

Read more at prnewswire.com